All In Biotech

Drug Trial Radar · NCT00285766

Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression

A Phase III, Open-Label Study of the Safety, Tolerability and Efficacy of the Selegiline Transdermal System in Elderly Subjects With Major Depression

Last checked: Nov 20, 2026Latest source record: Apr 22, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Aug 2002

Primary completion

Not stated

Study completion Jul 2005

Sponsor

Lead sponsor
Somerset PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 2, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Objective of this 16-week, open-label study is to assess the safety and tolerability of once daily application of three doses of STS during continuous dosing in the treatment of elderly subjects with major depression. Subjects will have study visits (clinic visits) at beginning of study (baseline) and study weeks 1, 3, 5, 8, 12, and 16.

Conditions

  • Major Depression

Interventions

  • Selegiline Transdermal SystemDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Mohammed Bari, M.D.

    Chula Vista, California

  • Charles Meredith, M.D.

    San Diego, California

  • Daniel Zimbroff, M.D.

    Upland, California

  • Kathleen Toups, M.D.

    Walnut Creek, California

  • Abbey Strauss, M.D.

    Boynton Beach, Florida

  • Barry Baumel, M.D.

    Miami Beach, Florida

  • Margarita Nunez, M.D.

    St. Petersburg, Florida

  • Mildred Farmer, M.D.

    St. Petersburg, Florida

  • Larry Eisner, M.D.

    Tamarack, Florida

  • Andrew Cutler, M.D.

    Winter Park, Florida

  • Robert Riesenberg, M.D.

    Atlanta, Georgia

  • James Hartford, M.D.

    Florence, Kentucky

  • Mitchel Kling, M.D.

    Baltimore, Maryland

  • Louise Beckett, M.D.

    Oklahoma City, Oklahoma

  • Penny Barnhart, M.D.

    Wichita Falls, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.